Ingrezza reduces cognitive and motor burdens in Huntington’s disease

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $12.5 billion biopharmaceutical company with impressive 22% revenue growth over the past year, reported new patient data showing that its drug Ingrezza (valbenazine) significantly reduced both cognitive and motor-related disease burdens in adults with Huntington’s disease chorea compared to placebo. InvestingPro analysis indicates the company maintains strong financial health with a "GREAT" overall rating.

The post-hoc analysis from the Phase 3 KINECT-HD study revealed improvements across multiple symptoms, including memory loss, decision-making abilities, mobility limitations, and swallowing problems. The findings will be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders Congress in Washington, D.C.

According to the data, patients treated with Ingrezza showed numerically larger reductions compared to placebo across all 18 cognition items and 32 of 33 motor items measured by the Huntington’s Disease Health Index (HD-HI). Statistically significant improvements were observed in several areas, including memory loss (-0.9 vs -0.2), reduced decision-making abilities (-1.0 vs -0.3), and problems with swallowing (-1.0 vs -0.3).

"These new patient-reported analyses highlight Ingrezza’s ability to reduce additional cognitive and motor-related challenges faced by those living with Huntington’s disease," said Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, in the press release.

Huntington’s disease affects approximately 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the condition. The progressive neurodegenerative disorder causes motor, cognitive, and psychiatric symptoms, with chorea (involuntary movement disorder) being one of the most common manifestations.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating tardive dyskinesia and Huntington’s disease chorea in adults. The medication is administered as a once-daily capsule and is available in both standard and sprinkle formulations.

The information in this article is based on a press release from Neurocrine Biosciences. According to InvestingPro, 8 analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s prospects. For detailed financial analysis and 7 additional exclusive ProTips, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Neurocrine Biosciences has presented new findings on the effectiveness of INGREZZA in improving the quality of life for older adults with tardive dyskinesia. The results were shared at the 2025 American Association of Nurse Practitioners National Conference, highlighting significant improvements in health-related quality of life for patients continuing treatment with INGREZZA. Additionally, Neurocrine Biosciences announced the appointment of Lewis Choi as the new Chief Information Officer, bringing 25 years of experience in information technology and artificial intelligence to the company. Choi’s role will focus on enhancing business operations and supporting the development and delivery of treatments. In analyst updates, Guggenheim has reaffirmed its Buy rating for Neurocrine Biosciences, maintaining a price target of $165.00, citing growth prospects and positive sales momentum. Similarly, RBC Capital maintained an Outperform rating with a price target of $145.00, expressing confidence in the company’s prescription growth and market stability. These developments signal a period of strategic growth and operational strengthening for Neurocrine Biosciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.